OMB APPROVAL
OMB Number: 3235-0145
Expires: December 31, 2005
Estimated average burden hours per response 11.00
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
Lifeline Therapeutics, Inc.
------------------------------------
(Name of Issuer)
Common Stock
---------------------------------------
(Title of Class of Securities)
53221T108
---------------------------------------
(CUSIP Number)
Paul Robert Myhill
Lisa Gail Myhill
3466 Willowrun Court
Castle Rock, CO 80109
Telephone: 720 488 1711
------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
October 26, 2004
---------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check
the following box [ ].
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Section 240.13d-7 for other
parties to whom copies are to be sent.
SCHEDULE 13D
CUSIP No. 53221T108 Page 2 of 6
- --------------------------------------------------------------------------------
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes)
SCHEDULE 13D
CUSIP No. 53221T108 Page 3 of 6
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON. I.R.S. IDENTIFICATION NO.OF ABOVE PERSON
Paul Robert Myhill
Lisa Gail Myhill
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
- ------------------------------------------------------------------- (b) [ ]
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 SOURCE OF FUNDS
PF
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e) [ ]
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Paul Robert Myhill: United States
Lisa Gail Myhill: United States
- --------------------------------------------------------------------------------
NUMBER OF | 7 | SOLE VOTING POWER
SHARES 0 shares
BENEFICIALLY -----------------------------------------------------
OWNED BY | 8 | SHARED VOTING POWER
EACH 4,699,890 shares
REPORTING -----------------------------------------------------
PERSON | 9 | SOLE DISPOSITIVE POWER
WITH 0 shares
-----------------------------------------------------
| 10 | SHARED DISPOSITIVE POWER
4,699,890 shares
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,699,890 shares as joint tenants
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES [ ]
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
28.7 %
- --------------------------------------------------------------------------------
SCHEDULE 13D
CUSIP No. 53221T108 Page 4 of 6
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
Paul Robert Myhill: IN
Lisa Gail Myhill: IN
Item 1. Security And Issuer
This Statement relates to the Common Stock of Lifeline Therapeutics, Inc.,
a company organized under the laws of the State of Colorado.
The principal executive offices of the Lifeline Therapeutics, Inc. are
located at 6400 South Fiddlers Green Circle, Suite 1750, Englewood, Colorado
80111.
Item 2. Identity and Background
The identities and residential addresses of the reporting persons are:
Paul Robert Myhill, 3466 Willowrun Court, Castle Rock, Colorado 80109; and
Lisa Gail Myhill, 3466 Willowrun Court, Castle Rock, Colorado 80109.
Mr. Myhill serves as the Vice President and a Director of Lifeline
Therapeutics, Inc., 6400 South Fiddlers Green Circle, Suite 1750, Englewood, CO
80111.
Mrs. Myhill is currently not employed.
The reporting persons have not been convicted in criminal proceedings of
the nature described in Item 2(d) of Schedule 13D in the last five years.
The reporting persons have not been parties to a civil proceeding of the
nature described in Item 2(e) of Schedule 13D in the last five years.
The reporting persons are both citizens of the United States.
SCHEDULE 13D
CUSIP No. 53221T108 Page 5 of 6
- --------------------------------------------------------------------------------
Item 3. Source and Amount of Funds or Other Consideration
This Schedule 13D reports the following transactions:
- -------------------------------------- -----------------------------------------
Securities Amount/Source of Funds
- -------------------------------------- -----------------------------------------
4,699,890 shares of common stock Mr. Myhill acquired the shares of common
stock pursuant to the terms of an
Agreement and Plan of Reorganization
between Lifeline Nutraceuticals
Corporation and Lifeline Therapeutics,
Inc., whereby the shareholders of
Lifeline Nutraceuticals exchanged their
outstanding common stock in Lifeline
Nutraceuticals for newly issued stock in
Lifeline Therapeutics, Inc.
- -------------------------------------- -----------------------------------------
4,699,890 shares of common stock On November 22, 2004, Mr. Myhill
transferred (as a gift) a joint tenancy
interest in the 4,699,890 shares of
Lifeline Therapeutics common stock to his
wife, Lisa Gail Myhill.
- -------------------------------------- -----------------------------------------
Item 4. Purpose of Transaction
The reporting persons acquired these shares for investment purposes.
Item 5. Interest in the Securities of the Issuer
(a) The reporting persons aggregate interest and percentage of common stock
of Lifeline Therapeutics, Inc. equal 4,699,890 shares (28.7% of the shares of
common stock outstanding). The shares of common stock described above are the
only interest the reporting persons have in Lifeline Therapeutics, Inc. common
stock.
(b) The reporting persons, individually, do not have sole voting or sole
dispositive power with respect to any shares of common stock in Lifeline
Therapeutics. The reporting persons have shared voting and dispositive power
with respect to 4,699,890 shares of common stock of Lifeline Therapeutics, Inc.,
which they hold as joint tenants.
(c) N/A
(d) N/A
(e) N/A
SCHEDULE 13D
CUSIP No. 53221T108 Page 6 of 6
- --------------------------------------------------------------------------------
Item 6. Contract, Arrangements, Understandings or Relationships with Respect to
Securities of the Issuer
None
Item 7. Material to be Filed as Exhibits
N/A
Signatures and Affidavits:
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: December 6, 2004 By: /s/ Paul Robert Myhill
-------------------------------------
Dated: December 6, 2004 By: /s/ Lisa Gail Myhill
-------------------------------------
ATTENTION: Intentional misstatements or omissions of fact constitute federal
criminal violations. (See 18USC1001)